The BAX Knockout CAL-27 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population of the human tongue squamous cell carcinoma line CAL-27, engineered for disruption of the BAX gene (BCL2-associated X protein). This loss-of-function product is supplied as a heterogeneous cell pool to avoid clonal artifacts, providing a robust platform for studying BAX-dependent apoptosis. The CRISPR/Cas9-mediated gene disruption eliminates BAX expression, allowing investigation of its role in apoptotic signaling. The polyclonal composition ensures diverse editing outcomes without clonal bias, and the cells are ready for direct culture experiments.
The parental CAL-27 cell line is a human epithelial model derived from a tongue squamous cell carcinoma, extensively employed in oral cancer research. It displays characteristics typical of oral squamous cell carcinoma, including aberrant proliferation and impaired apoptotic regulation. This line serves as a well-characterized system for investigating oncogenic signaling and treatment resistance. Its genetic and phenotypic features make it an ideal host for gene editing to dissect oral carcinogenesis and therapeutic response.
BAX functions as a critical pro-apoptotic effector of the intrinsic mitochondrial pathway. Following activation by upstream stress signals??transcriptionally by p53 and post-translationally by BIM, BID, PUMA, and NOXA??BAX translocates to mitochondria, where it oligomerizes to permeabilize the outer membrane. This triggers cytochrome c release, which binds APAF1 to recruit and activate caspase-9, subsequently activating caspase-3. BAX activity is restrained through heterodimerization with anti-apoptotic BCL2, BCL-XL, MCL1, and interactions with VDAC1. Genetic disruption of BAX abolishes this apoptotic cascade, enabling precise dissection of mitochondrial death signaling.
In the context of oral squamous cell carcinoma, where apoptosis resistance drives tumor progression and treatment failure, BAX inactivation offers a valuable tool. CAL-27 cells frequently maintain wild-type p53, positioning BAX as a critical mediator of p53-dependent cell death. By disrupting BAX, researchers can assess the reliance of this cancer line on mitochondrial apoptosis and investigate compensatory cell death mechanisms. This model is indispensable for delineating the apoptotic versus non-apoptotic contributions of chemotherapeutic agents in oral cancer. Furthermore, it allows interrogation of BAX interactions within the Bcl-2 network in a disease-relevant setting.
This BAX knockout polyclonal CAL-27 cell population supports diverse experimental applications. Apoptosis induction can be assessed via flow cytometry for Annexin V/PI staining and caspase-3/7 activity measurements. Western blotting and RT-qPCR confirm BAX ablation and monitor cytochrome c release, while co-immunoprecipitation maps Bcl-2 network alterations. Mitochondrial membrane potential assays (e.g., JC-1) and viability assays quantify death resistance. These cells are suitable for high-throughput screening of pro-apoptotic compounds and epistasis analysis of BAX with upstream regulators and downstream caspases. For further technical details, please contact Ascent Research.
